Suven Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Suven Pharmaceuticals has a total shareholder equity of ₹20.3B and total debt of ₹90.7M, which brings its debt-to-equity ratio to 0.4%. Its total assets and total liabilities are ₹25.1B and ₹4.8B respectively. Suven Pharmaceuticals's EBIT is ₹2.7B making its interest coverage ratio 46.6. It has cash and short-term investments of ₹6.6B.
Key information
0.4%
Debt to equity ratio
₹90.70m
Debt
| Interest coverage ratio | 46.6x |
| Cash | ₹6.56b |
| Equity | ₹20.28b |
| Total liabilities | ₹4.77b |
| Total assets | ₹25.06b |
Recent financial health updates
These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely
Dec 15
Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?
May 12These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely
Nov 30Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly
Aug 04Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?
Mar 08Recent updates
These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely
Dec 15Robust Earnings May Not Tell The Whole Story For Suven Pharmaceuticals (NSE:SUVENPHAR)
Aug 03Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?
May 12Suven Pharmaceuticals Limited (NSE:SUVENPHAR) Investors Are Less Pessimistic Than Expected
Mar 26Here's Why We Think Suven Pharmaceuticals (NSE:SUVENPHAR) Is Well Worth Watching
Mar 07These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely
Nov 30Do Suven Pharmaceuticals's (NSE:SUVENPHAR) Earnings Warrant Your Attention?
Sep 03Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly
Aug 04Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report
Jun 11With EPS Growth And More, Suven Pharmaceuticals (NSE:SUVENPHAR) Is Interesting
Apr 13Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?
Mar 08Can Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) ROE Continue To Surpass The Industry Average?
Feb 08Financial Position Analysis
Short Term Liabilities: SUVENPHAR's short term assets (₹11.7B) exceed its short term liabilities (₹2.4B).
Long Term Liabilities: SUVENPHAR's short term assets (₹11.7B) exceed its long term liabilities (₹2.4B).
Debt to Equity History and Analysis
Debt Level: SUVENPHAR has more cash than its total debt.
Reducing Debt: SUVENPHAR's debt to equity ratio has reduced from 18.7% to 0.4% over the past 5 years.
Debt Coverage: SUVENPHAR's debt is well covered by operating cash flow (3129.5%).
Interest Coverage: SUVENPHAR's interest payments on its debt are well covered by EBIT (46.6x coverage).